Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1483792

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus

Provisionally accepted
Xu He Xu He 1Wei Zhao Wei Zhao 1Peihang Li Peihang Li 1Yinjiang Zhang Yinjiang Zhang 1Guohua Li Guohua Li 2Hongyu Su Hongyu Su 3Binan Lu Binan Lu 1*Zongran Pang Zongran Pang 1*
  • 1 Minzu University of China, Beijing, China
  • 2 Dali Bai Autonomous Prefecture People's Hospital, Dali, China
  • 3 Chengde Medical University, Chengde, Shanghai Municipality, China

The final, formatted version of the article will be published soon.

    Glucagon-like peptide-1 (GLP-1) is a 30-amino acid intestinal insulin-stimulating factor, which is mainly secreted by L cells in the distal ileum and colon. It has various physiological functions, such as promoting insulin secretion and synthesis, stimulating β-cell proliferation, inducing islet regeneration, inhibiting β-cell apoptosis and glucagon release, delaying gastric emptying and controlling appetite, etc. It plays a role through a specific GLP-1 receptor (GLP-1R) distributed in many organs or tissues and participates in the regulation of glucose homeostasis in the body. GLP-1 receptor agonists (GLP-1RAs) has the similar physiological function of GLP-1. Because of its structural difference from natural GLP-1, it is not easy to be degraded by dipeptidyl peptidase-4 (DPP-4), thus prolonging the action time. GLP-1RAs have been recognized as a new type of hypoglycemic drugs and widely used in the treatment of type 2 diabetes mellitus (T2DM). Compared with other non-insulin hypoglycemic drugs, it can not only effectively reduce blood glucose and glycosylated hemoglobin (HbA1c), but also protect cardiovascular system, nervous system and kidney function without causing hypoglycemia and weight gain. Therefore, GLP-1RAs has good application prospects and potential for further development.

    Keywords: GLP-1, GLP-1RAs, T2DM, Glucose, Mechanism

    Received: 20 Aug 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 He, Zhao, Li, Zhang, Li, Su, Lu and Pang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Binan Lu, Minzu University of China, Beijing, China
    Zongran Pang, Minzu University of China, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.